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EXECUTIVE BRIEF
DELIVERING 
HEALTHCARE 
IN ASIA
Demographic shifts and changes in population age 
structure are changing global dynamics in healthcare. World 
population is expected to grow by 2.4 billion between 2013 
and 2050, touching 9.6 billion by 2050. More importantly, a 
massive 96 percent (2.3 billion) of this increase will be seen 
in emerging and developing countries alone, as population 
growth levels off in industrialised nations.1 There is also 
expected to be an increase in global life expectancy, which 
is estimated to rise from 69 years (for those born in 2005-10) to 
76 years (for those born in 2045-50).2 At the same time, 
the world will see a growing burden of chronic diseases such as 
cancer, diabetes, and cardiovascular and respiratory diseases; 
and the World Health Organization (WHO) has predicted that 
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over 50 billion people will succumb to chronic diseases by 
2030, up from 38 billion in 2012.3
The larger population pool, combined with more people 
living longer but not necessarily healthier lives, has a direct 
impact on worldwide healthcare expenditure, which currently 
stands at 10.6 percent of global GDP.4 In the United States, 
spending on healthcare accounts for 16.2 percent of GDP, 
while health expenditures in developing countries are growing 
at a rate well above the global average. Between 2010 and 
2015, healthcare costs in China and India have risen by 
15.2 percent and 12.5 percent per annum respectively.5 And, 
based on trends in global demographics, these numbers will 
continue to rise at an alarming rate in the foreseeable future.
INCREASE IN HEALTHCARE 
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surgery are expensive. However, when compared to the cost of 
one, or possibly two open heart surgeries, weeks of 
hospitalisation and post operative care, time lost away from 
work and home—not to mention the discomfort of the patient—it 
is actually a very good deal.
Technological advancements have also been made in the 
field of diagnostic testing. Seventy percent of all clinical 
GHFLVLRQVDUHLQRQHZD\RUWKHRWKHULQÁXHQFHGE\GLDJQRVWLFV
In order to determine the right treatment, an accurate diagnosis 
is essential. There are two ways of going about them. 
First, there is in-vivo medicine, where clinical images of 
the body are generated, for example through a computed 
tomography (CT) scan. Based on the images, a radiologist 
is able to make a diagnosis. The second method is 
in-vitro testing, where samples of bodily fluids such as urine 
and/or blood are taken from the patient and then analysed 
in a lab. Both aim to identify diseases early, to guide treatment 
and therapy, and to reduce cost of healthcare delivery.
It is said that up to 75 percent of cancer treatments are 
ineffective.6 Comprehensive cancer diagnostics are now able 
to meet this challenge. The liquid biopsy test, for example, is 
used to diagnose lung cancer, one of the most common types 
RI FDQFHU7KH WHVW LV DEOH WR GHWHUPLQH WKH VSHFLÀF WUHDWPHQW
relevant mutations in the cancer from a single blood sample, 
making it a non-invasive, painless and low-risk alternative to a 
biopsy. Once the type of tumour is ascertained from the 
Healthcare systems around the world have to find new 
ways to keep costs down while improving the reach and quality 
of medical services. The demand for professional, affordable, 
entry-level healthcare solutions is intensifying. While developed 
countries face the challenge of controlling costs and raising 
quality of care, developing countries need to improve access 
to healthcare while avoiding the implied cost trajectory.
The question that I address here is: How can innovation 
in healthcare contribute to solving these challenges? The medical 
ÀHOG LV D IURQWUXQQHU LQGHYHORSLQJQHZGHYLFHV DQG LQQRYDWLYH
procedures, and coming up with breakthrough technologies. But 
can these make a positive impact on the health of the world’s 
population? Is investing in high-end innovation in medical 
technology a blessing or a curse?
Better outcomes at lower costs 
Let’s take an example of how innovation has been shown to 
improve health outcomes and reduce costs at the same time. Ten 
years back, a patient requiring aortic valve repair would have 
to undergo open-heart surgery. If for some reason the surgery 
was not successful, or if there were other complications, the 
procedure would most likely have to be repeated, or the 
prognosis for the patient would have been bad. Today, the 
same procedure can be done using sophisticated imaging 
and minimally invasive technology, with a positive outcome 
for the patient just from a minor cut. 
What is more, real-time information from multiple 
imaging systems can be used, simultaneously, to detect 
abnormal tissues, and correct it immediately—without the 
need for a second procedure. And as the procedure is 
minimally invasive, the patient can usually be discharged 
sooner than before, sometimes even the next day. The 
multi-imaging system approach and minimally invasive 
Healthcare systems around the world 
have to find new ways to keep costs 
down while improving the reach and 
quality of medical services.
Two ways to determine the right treatment
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blood sample, the treatment can be focused and effective. So 
the more we invest upfront in understanding the medical 
condition through diagnostic testing, the better it is. Otherwise 
the treatments that follow can end up being ineffective, 
repetitive and quite costly. 
Innovation in healthcare is not only about the high-
end. It is also about improving access and reducing the cost 
of high quality healthcare, and to have as many people as 
SRVVLEOH EHQHÀW IURP WHFKQRORJ\ 7KLV LV SDUWLFXODUO\ UHOHYDQW 
for Asia.
The uniqueness of Asia
Asia, with the vast majority of its population residing in 
emerging markets, is in dire need of better healthcare delivery 
to its large and remote populations. Therefore, it is a region 
with tremendous opportunities for technological innovations 
to enable accessible, affordable and quality healthcare. 
While developing basic healthcare infrastructure calls for 
common strategies across countries, there are inherent 
differences between developed and emerging markets 
(and also within each of these categories). The needs 
and means in countries such as Indonesia and Thailand 
are certainly different from, say Singapore or Japan—which 
fundamentally changes how companies work with patients 
and healthcare providers. 
Access and affordability are two key issues in Asia. Many 
people in this region live in remote areas and have to travel long 
distances to get access to and receive medical treatment, 
a journey which is hard to take when one is really sick. Look at 
the coverage of Southeast Asia when it comes to modalities 
such as CT scanners. In the Philippines, we find only 
one scanner per one million population—compared to 
around one to 40 in Germany or the United States. And 
there, not only is the coverage greater, infrastructure is also 
more advanced, which shortens travel time considerably.
And accessibility of healthcare also comes down to a matter 
of who can actually afford it—for many people, an X-ray 
scan will practically cost an arm and a leg. While basic 
healthcare is provided for under public healthcare schemes in 
some Asian countries, many additional treatments 
must be paid out of the patient’s own pocket. In India, 
for example, 75 percent of treatments are being paid 
privately by the patient.
FINANCING OPTIONS
Many developed countries, such as Germany, offer a completely 
VWDWHÀQDQFHG V\VWHPZLWK D YHU\ZHOOVWUXFWXUHG UHLPEXUVHPHQW
scheme, eliciting the highest standards in productivity from 
providers. Countries in Asia, in contrast, mostly exhibit a 
fee-for-service type model, depicting environments more 
akin to supply and demand dynamics. Premiums are afforded 
to those who can differentiate their service offerings and 
provide augmented value propositions through better 
technology, better qualifications, or even more convenient 
locations. There is also still a lot of room for entrepreneurs 
in the private segment, constituting many of the hugely 
successful private hospital chains in this part of the world— 
these types of opportunities simply don’t exist to the same 
extent in highly regulated and developed markets of 
Western Europe.
When looking at emerging markets, the discussion 
then shifts to other considerations such as establishing 
basic healthcare systems and moving towards a more 
insurance-based framework that is subsidised by the 
government—a transition that is currently underway in 
Indonesia. But even if the economic outlook is good for 
many countries in Southeast Asia, it won’t be possible for 
governments to fund a comprehensive insurance system, as 
the financial burden would simply be too great. Just think of 
chronic diseases such as diabetes and the treatment costs per 
patient! This is the case even when the cost of care and the 
subsidisation rates are often low due to young populations 
and low levels of care.
Singapore is a mature market and characteristically closer in 
comparison to developed markets like Australia, New Zealand, or 
even Europe. As a wealthy country with an advanced healthcare 
system, Singapore sets the standards for the rest of the region. 
It serves as a reference point for many countries in terms of the 
regulatory environment and the infrastructure of healthcare 
delivery systems, especially for Southeast Asia. 
So how do some of the global key trends translate into the 
unique Asian environment?
Consolidation and industrialisation
Industry-wide, we notice shifts towards consolidation and 
industrialisation. What do I mean by consolidation? Healthcare 
providers are merging to gain competitive advantages by 
achieving economies of scale and offering more specialised 
Innovation in healthcare is not only 
about the high-end.
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care. Within Asia Pacific, Australia is 
a very extreme example of a highly 
consolidated market, which has only a 
handful of healthcare providers that run 
very large-scale operations. Other 
countries in the region are moving 
towards consolidation, too.  In India, for 
example, currently about 80 percent of 
the healthcare providers are unorganised. 
As the market starts getting served by 
more organised and bigger players, the 
patients can expect more professional care 
becoming available at reasonable cost.
The second trend is towards 
industrialisation in healthcare, which 
VSHFLÀFDOO\ DGGUHVVHV WKH QHHG WR ORZHU 
costs while improving outcomes, and 
doing so in a repeatable manner. Look at 
laboratories, for example. The way they 
work has changed a great deal over the 
past years—a lot more is being achieved 
with fewer resources. Nowadays, it 
is like looking at a factory: There are 
centralised, highly productive labs, 
managing up to 100,000 tests a day.
In line with those developments, 
Siemens Healthineers, the medical 
technology arm of Siemens, has designed 
a new automated laboratory solution 
which combines immunoassay and 
chemistry testing. It utilises a magnetic 
transport system that works ten times 
faster than conventional tracks. And 
by producing over 400 immunoassay 
tests per hour, it boasts the industry’s 
highest productivity per square metre. 
Due to the high degree of automation and 
clever routing of test samples, urgent results 
can be provided more quickly—which in 
some cases can be crucial for the survival 
of a patient. 
Solutions for remote areas
For remote areas, point-of-care testing 
is ideal, as it can be done on the spot, 
using urine test strips to detect any 
kind of inflammation. Blood samples 
can be taken at decentralised collection 
centres and then sent to central hubs 
for analysis in larger cities. This field 
is currently unfolding. There are a few 
centres in India, such as Thyrocare, 
and in Southeast Asia, such as Prodia 
in Indonesia and Medic in Vietnam. 
The case looks different for 
medical imaging. Here, the patient 
needs to be where the scanner is 
and vice versa. But what about the 
highly-trained radiologists who are 
reading the images? They can actually 
deliver their diagnosis remotely, a 
process that is called teleradiology and 
is a great means of improving the quality 
of healthcare in remote or rural areas. 
Another option is to develop 
products that address the particular 
needs of healthcare providers in remote 
areas. To give an example, Siemens 
Healthineers has come up with a new 
CT scanner with simplified features 
and small footprint, which comes at a 
fraction of the price of its high-end 
machines—an important consideration 
when budgets are limited. Patients in 
India already benefit from one of the 
ÀUVW WKUHH LQVWDOOHG V\VWHPV ZRUOGZLGH³ 
and there is more to come. This shows 
how pioneering innovation is not only 
about serving the high-end segment, 
but also has accessibility and affordability 
in mind. 
Future priorities
Global healthcare needs will continue 
to grow, be it in industrialised nations 
or emerging markets. The pace of 
technological innovation will also 
continue. So what can healthcare 
businesses do to leverage innovation 
to find more suitable ways to support 
healthcare needs,  especial ly  in 
emerging countries?
First,  partnerships are key. 
Technology is a great enabler to link 
healthcare providers, health solution 
providers and patients, as well as their 
data and knowledge. Such an integrated 
ecosystem can pave the way for the 
digital transformation of healthcare. 
For example, when it comes to product 
development, companies that are leading 
the market are co-creating solutions by 
working with hospitals, universities and 
research institutes. 
Second, I believe localisation can 
drive business success. Siemens 
Healthineers, for example, has set 
up a factory in Goa, India, to 
design and produce basic X-ray 
systems that are also sold in the 
country. This ensures that local 
market needs are met and products 
are readily accessible. In addition, 
Bangalore, India, is a fantastic example 
of how local knowledge can influence 
the global business of companies. 
Siemens Healthineers has around 
1,500 software engineers employed 
onsite whose vast knowledge has 
a great impact on product development 
on not just at a local but at a global scale.
Overall, in order to be successful, 
medtech companies have to make 
the move from product-centric towards 
value- and patient-centric business 
models: Healthcare is not only about 
the latest and greatest products. It is 
first and foremost about understanding 
the needs of healthcare providers and 
their patients here in Asia, and 
working together to answer those 
with great care. I would also like to 
mention the potential of IT in this 
regard. Already today, we see what 
artificial intelligence and deep machine 
learning can do to support clinical 
decision-making—and for sure, these 
capabilities when developed will 
have a major role to play in the future 
of healthcare. 
Where does this leave us in terms 
of high-end innovation in medical 
technology? There is no black and 
white. Even if sometimes one can 
get the impression that the field of 
medical technology may at times be 
overengineered, high-end innovation 
does not necessarily mean expensive 
machines—it can also mean an 
investment paying off in the long-term. 
Or it can mean innovation trickling 
down to the lower end of the price 
spectrum, which is great because this is 
ZKHUH PDQ\ SHRSOH FDQ DFWXDOO\ EHQHÀW 
from such technology, especially here 
in Asia. Thus, it can ensure that every 
penny used for pioneering in the 
field of healthcare is money well spent.
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